Roche and reMYND will make Parkinson's and Alzheimer's drugs

09/7/2010 | Reuters

Roche Holding is collaborating with Belgium's reMYND to develop two of the latter's preclinical compounds, which suppress tau neurotoxicity in Alzheimer's disease and alpha-synuclein neurotoxicity in Parkinson's disease. ReMYND might receive from Roche more than $637 million in milestone fees, plus royalties.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA